255 related articles for article (PubMed ID: 18383395)
1. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.
Nishimoto N; Nakahara H; Yoshio-Hoshino N; Mima T
Arthritis Rheum; 2008 Apr; 58(4):1197-200. PubMed ID: 18383395
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.
Cañas CA; Cañas F; Izquierdo JH; Echeverri AF; Mejía M; Bonilla-Abadía F; Tobón GJ
J Clin Rheumatol; 2014 Apr; 20(3):125-9. PubMed ID: 24662551
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide.
Kong X; Zhang X; Lv P; Cui X; Ma L; Chen H; Liu H; Lin J; Jiang L
Int J Cardiol; 2018 Sep; 266():222-228. PubMed ID: 29729868
[TBL] [Abstract][Full Text] [Related]
4. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers.
Salvarani C; Magnani L; Catanoso MG; Pipitone N; Versari A; Dardani L; Pulsatelli L; Meliconi R; Boiardi L
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S90-3. PubMed ID: 22410150
[TBL] [Abstract][Full Text] [Related]
5. [Tocilizumab for refractory Takayasu arteritis with aortic aneurysm].
Frikha F; Garbaa S; Bouattour Y; Snoussi M; Loukil H; Ben Salah R; Bahloul Z
J Med Vasc; 2019 May; 44(3):237-239. PubMed ID: 31029281
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis.
Lo Gullo A; Mandraffino G; Aragona CO; Molica Colella A; Saitta A; Imbalzano E
Reumatismo; 2017 Dec; 69(4):184-188. PubMed ID: 29320845
[TBL] [Abstract][Full Text] [Related]
7. Successful tocilizumab treatment in a child with refractory Takayasu arteritis.
Bravo Mancheño B; Perin F; Guez Vázquez Del Rey Mdel M; García Sánchez A; Alcázar Romero PP
Pediatrics; 2012 Dec; 130(6):e1720-4. PubMed ID: 23147976
[TBL] [Abstract][Full Text] [Related]
8. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis.
Youngstein T; Peters JE; Hamdulay SS; Mewar D; Price-Forbes A; Lloyd M; Jeffery R; Kinderlerer AR; Mason JC
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S11-8. PubMed ID: 24093733
[TBL] [Abstract][Full Text] [Related]
9. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis.
Goel R; Danda D; Kumar S; Joseph G
Int J Rheum Dis; 2013 Dec; 16(6):754-61. PubMed ID: 24382284
[TBL] [Abstract][Full Text] [Related]
10. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy.
Atreya R; Billmeier U; Rath T; Mudter J; Vieth M; Neumann H; Neurath MF
World J Gastroenterol; 2015 Dec; 21(45):12963-9. PubMed ID: 26668517
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of blocking IL-6 receptor.
Mima T; Nishimoto N
Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
[TBL] [Abstract][Full Text] [Related]
12. Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting.
Yano T; Osanami A; Shimizu M; Katano S; Nagano N; Kouzu H; Koyama M; Muranaka A; Harada R; Doi H; Kawaharada N; Miura T
ESC Heart Fail; 2019 Aug; 6(4):894-897. PubMed ID: 31297975
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center.
Tombetti E; Franchini S; Papa M; Sabbadini MG; Baldissera E
J Rheumatol; 2013 Dec; 40(12):2047-51. PubMed ID: 24187104
[TBL] [Abstract][Full Text] [Related]
14. Exacerbation of Ulcerative Colitis with Tocilizumab: A Report of Two Cases, One with Takayasu Arteritis and the Other with Relapsing Polychondritis.
Hanioka Y; Shimizu K; Yamagami K; Yao S; Nakamura R; Nakamura T; Goto H
Intern Med; 2021 May; 60(10):1615-1620. PubMed ID: 33281154
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for the treatment of patients with refractory Takayasu arteritis.
Nakaoka Y; Higuchi K; Arita Y; Otsuki M; Yamamoto K; Hashimoto-Kataoka T; Yasui T; Ikeoka K; Ohtani T; Sakata Y; Shima Y; Kumanogoh A; Yamauchi-Takihara K; Tanaka T; Kishimoto T; Komuro I
Int Heart J; 2013; 54(6):405-11. PubMed ID: 24309452
[TBL] [Abstract][Full Text] [Related]
16. Refractory Takayasu arteritis successfully treated with infliximab.
Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
[TBL] [Abstract][Full Text] [Related]
17. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
Murakami M; Nishimoto N
Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
[TBL] [Abstract][Full Text] [Related]
18. Relapses in three patients with Takayasu arteritis under tocilizumab treatment detected by contrast enhanced ultrasound.
Czihal M; Lottspeich C; Schröttle A; Treitl KM; Treitl M; Leipe J; Schulze-Koops H; Hoffmann U; Dechant C
Vasa; 2018 Feb; 47(2):149-152. PubMed ID: 29271720
[TBL] [Abstract][Full Text] [Related]
19. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
20. New treatment strategies in large-vessel vasculitis.
Unizony S; Stone JH; Stone JR
Curr Opin Rheumatol; 2013 Jan; 25(1):3-9. PubMed ID: 23114585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
